AbbVie

ABBV
Delayed Nyse - 05/24 10:00:40 pm
80.06USD
-1.34%
Prev.81.1500
Open81.0900
High81.1000
Low79.8701
Volume3 872 999
Financials
Sales 2019 32 773 M
EBIT 2019 15 460 M
R. net 2019 10 641 M
Debt 2019 32 289 M
Rend. 2019 5,30%
P/E ratio 2019 11,00
P/E ratio 2020 9,46
EV / Sales 2019 4,60x
EV / Sales 2020 4,21x
Capitalization 118 B
Company
AbbVie specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with...
Sector :
Pharmaceuticals - NEC
Calendar :
2019-07-28 Earnings Release
Trading Rating :
Investor Rating :
Latest news
05/23ABBVIE : reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL)
AQ
05/21ABBVIE : Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis
AQ
05/20ABBVIE : Provides Update on Depatuxizumab Mafodotin, an Investigational Medicine for Newly Diagnosed Glioblastoma an Aggressive Form of Brain Cancer
AQ
05/20ABBVIE : Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer
AQ
05/17ABBVIE : halts enrollment after brain cancer trial misses goal, shares fall
RE
05/17ABBVIE : Glioblastoma Drug Misses Primary Endpoint
DJ
05/17ABBVIE : Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer
PR
05/16ABBVIE : Announces US FDA Approval of VENCLEXTA as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBearishBearish
Resistance81,684,089,5
Spread/Res.-1,9%-4,7%-11%
Spread/Supp.1,0%4,1%3,4%
Support79,376,977,5